Genentech Says PGx-Guided Melanoma Drug Meets Primary Endpoints in Phase III Trial
January 19, 2011
Genentech Says PGx-Guided Melanoma Drug Meets Primary Endpoints in Phase III Trial
The drug, an oral kinase inhibitor that targets the oncogenic BRAF V600 mutation, is being co-developed with an investigational diagnostic test from Roche Molecular Diagnostics to identify patients whose tumors carry the mutated gene.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - UK's NICE Cites Lack of Response Markers for BMS' Yervoy as Factor in Negative Recommendation
October 19, 2011 / Pharmacogenomics Reporter - Roche Says FDA-Approved BRAF Test Is Better Than Sanger-based LDTs, but is it Enough to Sway Labs?
September 28, 2011 / Pharmacogenomics Reporter - FDA's Reorganization of Oncology Office May Be Good for PGx-Guided Drugs
September 14, 2011 / Pharmacogenomics Reporter - FDA Simultaneously Approves Roche/Plexxikon's Drug, Companion Dx for BRAF-Mutated Melanoma
August 17, 2011 / Pharmacogenomics Reporter